NCT01501448

Brief Summary

The recent controversy regarding the use of pill for cycle planning in GnRH antagonists IVF cycle has driven the search for new ways to plan IVF cycles in order to avoid weekends or to equally distribute the workload. Recently, mid-late luteal phase oral estrogens seem to be as good as the pill. The investigators will compare OCP vs oral estrogens to plan the initiation of IVF cycles.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
118

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jan 2012

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 27, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 29, 2011

Completed
3 days until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2012

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2013

Completed
Last Updated

March 22, 2016

Status Verified

March 1, 2016

Enrollment Period

4 months

First QC Date

December 27, 2011

Last Update Submit

March 20, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Implantation rate

    number of embryonic sacs visible by ultrasound divided by the number of embryos transferred

    20 days after the embryo transfer

Study Arms (2)

OCP

ACTIVE COMPARATOR
Drug: Levonorgestrel and ethinylestradiol

Oral estradiol valerate

ACTIVE COMPARATOR
Drug: Estradiol valerate

Interventions

30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days

OCP

4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle

Oral estradiol valerate

Eligibility Criteria

Age18 Years - 38 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • st or 2nd IVF cycle
  • BMI \<30 kg/m2
  • regular menstrual cycles
  • basal FSH \<10IU and E2 \<60pg/mL

You may not qualify if:

  • polycystic ovaries
  • endometriosis
  • previous ovarian surgery
  • previous low ovarian response

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IVI Madrid

Madrid, Madrid, 28223, Spain

Location

Related Publications (1)

  • Hauzman EE, Zapata A, Bermejo A, Iglesias C, Pellicer A, Garcia-Velasco JA. Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial. Reprod Biol Endocrinol. 2013 Sep 28;11:96. doi: 10.1186/1477-7827-11-96.

MeSH Terms

Conditions

Infertility

Interventions

Ethinyl Estradiol-Norgestrel CombinationEstradiol

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

Ethinyl EstradiolNorpregnatrienesNorpregnanesNorsteroidsSteroidsFused-Ring CompoundsPolycyclic CompoundsNorgestrelNorpregnenesEstrogenic Steroids, AlkylatedEstradiol CongenersGonadal Steroid HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsEstrenesEstranes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 27, 2011

First Posted

December 29, 2011

Study Start

January 1, 2012

Primary Completion

May 1, 2012

Study Completion

February 1, 2013

Last Updated

March 22, 2016

Record last verified: 2016-03

Locations